GALECTIN THERAPEUTICS INC Form 8-K June 15, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

June 15, 2011

**Date of Report (Date of earliest event reported)** 

# GALECTIN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

NEVADA 000-32877 04-3562325

## Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

(State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)
7 WELLS AVENUE

### **NEWTON, MASSACHUSETTS**

02459

(Address of principal executive offices) (Zip Code)

(617) 559-0033

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

#### **Item 8.01 Other Events**

Attached hereto as Exhibit 99.1 is a press release issued on June 15, 2011 by Galectin Therapeutics Inc. announcing that FINRA has approved the change of the Company s stock trading symbol to GALT effective at the opening of trading on June 16, 2011.

### **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

### Exhibit

No. Exhibit Description

99.1 Press release dated June 15, 2011

## Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

By: /s/ Anthony D. Squeglia Anthony D. Squeglia Chief Financial Officer

Date: June 15, 2011